Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?

H. Noskova, M. Kyr, K. Pal, T. Merta, P. Mudry, K. Polaskova, TC. Ivkovic, S. Adamcova, T. Hornakova, M. Jezova, L. Kren, J. Sterba, O. Slaby,

. 2020 ; 12 (1) : . [pub] 20200117

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005332

Grantová podpora
16-33209A Ministerstvo Zdravotnictví Ceské Republiky
supplying FoundationOne Heme tests Roche
NV16-33209A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Tumor mutational burden (TMB) is an emerging genomic biomarker in cancer that has been associated with improved response to immune checkpoint inhibitors (ICIs) in adult cancers. It was described that variability in TMB assessment is introduced by different laboratory techniques and various settings of bioinformatic pipelines. In pediatric oncology, no study has been published describing this variability so far. METHODS: In our study, we performed whole exome sequencing (WES, both germline and somatic) and calculated TMB in 106 patients with high-risk/recurrent pediatric solid tumors of 28 distinct cancer types. Subsequently, we used WES data for TMB calculation using an in silico approach simulating two The Food and Drug Administration (FDA)-approved/authorized comprehensive genomic panels for cancer. RESULTS: We describe a strong correlation between WES-based and panel-based TMBs; however, we show that this high correlation is significantly affected by inclusion of only a few hypermutated cases. In the series of nine cases, we determined TMB in two sequentially collected tumor tissue specimens and observed an increase in TMB along with tumor progression. Furthermore, we evaluated the extent to which potential ICI indication could be affected by variability in techniques and bioinformatic pipelines used for TMB assessment. We confirmed that this technological variability could significantly affect ICI indication in pediatric cancer patients; however, this significance decreases with the increasing cut-off values. CONCLUSIONS: For the first time in pediatric oncology, we assessed the reliability of TMB estimation across multiple pediatric cancer types using real-life WES and in silico analysis of two major targeted gene panels and confirmed a significant technological variability to be introduced by different laboratory techniques and various settings of bioinformatic pipelines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005332
003      
CZ-PrNML
005      
20200518104715.0
007      
ta
008      
200511s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers12010230 $2 doi
035    __
$a (PubMed)31963488
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Noskova, Hana $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic. Department of Pediatric Oncology, University Hospital Brno, 613 00 Brno, Czech Republic.
245    10
$a Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision? / $c H. Noskova, M. Kyr, K. Pal, T. Merta, P. Mudry, K. Polaskova, TC. Ivkovic, S. Adamcova, T. Hornakova, M. Jezova, L. Kren, J. Sterba, O. Slaby,
520    9_
$a BACKGROUND: Tumor mutational burden (TMB) is an emerging genomic biomarker in cancer that has been associated with improved response to immune checkpoint inhibitors (ICIs) in adult cancers. It was described that variability in TMB assessment is introduced by different laboratory techniques and various settings of bioinformatic pipelines. In pediatric oncology, no study has been published describing this variability so far. METHODS: In our study, we performed whole exome sequencing (WES, both germline and somatic) and calculated TMB in 106 patients with high-risk/recurrent pediatric solid tumors of 28 distinct cancer types. Subsequently, we used WES data for TMB calculation using an in silico approach simulating two The Food and Drug Administration (FDA)-approved/authorized comprehensive genomic panels for cancer. RESULTS: We describe a strong correlation between WES-based and panel-based TMBs; however, we show that this high correlation is significantly affected by inclusion of only a few hypermutated cases. In the series of nine cases, we determined TMB in two sequentially collected tumor tissue specimens and observed an increase in TMB along with tumor progression. Furthermore, we evaluated the extent to which potential ICI indication could be affected by variability in techniques and bioinformatic pipelines used for TMB assessment. We confirmed that this technological variability could significantly affect ICI indication in pediatric cancer patients; however, this significance decreases with the increasing cut-off values. CONCLUSIONS: For the first time in pediatric oncology, we assessed the reliability of TMB estimation across multiple pediatric cancer types using real-life WES and in silico analysis of two major targeted gene panels and confirmed a significant technological variability to be introduced by different laboratory techniques and various settings of bioinformatic pipelines.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kyr, Michal $u Department of Pediatric Oncology, University Hospital Brno, 613 00 Brno, Czech Republic. Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.
700    1_
$a Pal, Karol $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic. Department of Hematology, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
700    1_
$a Merta, Tomas $u Department of Pediatric Oncology, University Hospital Brno, 613 00 Brno, Czech Republic. Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.
700    1_
$a Mudry, Peter $u Department of Pediatric Oncology, University Hospital Brno, 613 00 Brno, Czech Republic. Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.
700    1_
$a Polaskova, Kristyna $u Department of Pediatric Oncology, University Hospital Brno, 613 00 Brno, Czech Republic. Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.
700    1_
$a Ivkovic, Tina Catela $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic.
700    1_
$a Adamcova, Sona $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic.
700    1_
$a Hornakova, Tekla $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic.
700    1_
$a Jezova, Marta $u Department of Pathology, University Hospital Brno, 62500 Brno, Czech Republic.
700    1_
$a Kren, Leos $u Department of Pathology, University Hospital Brno, 62500 Brno, Czech Republic.
700    1_
$a Sterba, Jaroslav $u Department of Pediatric Oncology, University Hospital Brno, 613 00 Brno, Czech Republic. Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic. Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 60200 Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, 62500 Brno, Czech Republic. Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic. Department of Pathology, University Hospital Brno, 62500 Brno, Czech Republic.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 1 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31963488 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200518104715 $b ABA008
999    __
$a ind $b bmc $g 1524262 $s 1095387
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 1 $e 20200117 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a 16-33209A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a supplying FoundationOne Heme tests $p Roche
GRA    __
$a NV16-33209A $p MZ0
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace